Statin Drug‐Drug Interactions: Pharmacokinetic Basis of FDA Labeling Recommendations and Comparison Across Common Tertiary Clinical Resources

Documenti analoghi

• Clinical Pharmacology Guidances Advancing Drug Development and Regulatory Assessment: Role and Opportunities
  di: Anuradha Ramamoorthy, et al.
  Pubblicazione: (2025)
• Addressing Drug–Drug Interaction Knowledge Gaps at the Time of Approval: An Analysis of FDA Postmarketing Requirements and Commitments from 2009 to 2023
  di: Sarah Ridge, et al.
  Pubblicazione: (2024)
• The US Food and Drug Administration's Model‐Informed Drug Development Meeting Program: From Pilot to Pathway
  di: Rajanikanth Madabushi, et al.
  Pubblicazione: (2024)
• Drug Administration via Enteral Feeding Tubes: A Landscape Analysis of Information in Drug Product Labeling
  di: Sherbet Samuels, et al.
  Pubblicazione: (2026)
• Evaluation and Mitigation of Time‐Dependent Confounding Effects in Conventional Exposure‐Response Analyses for Oncology Drugs
  di: Xuefen Yin, et al.
  Pubblicazione: (2025)